JP-2026001077-A5 -

Dates

Publication Date

20260507

Application Date

20250924

Description

Example 10. Treatment of atopic dermatitis with anti-IL-13/IL-18 bispecific antibody. Subjects with atopic dermatitis are administered the bispecific antibody described herein. At week 16, compared to placebo-treated subjects, the subjects achieve a greater reduction in one or more signs and/or symptoms of atopic dermatitis. The inventions described in the original claims of this application are listed below. [Invention 1] It is a multispecific antibody, a. A first portion comprising a first light chain variable domain (VL1) and a first heavy chain variable domain (VH1) that specifically bind to interleukin-18 (IL-18), b. A second portion comprising a second light chain variable domain (VL2) and a second heavy chain variable domain (VH2) that specifically bind to interleukin-13 (IL-13) The multispecific antibody comprising the above. [Invention 2] A bispecific antibody, as described in Invention 1, which is a multispecific antibody. [Invention 3] The VH1 and VH2 include complementarity determination regions (CDRs) HCDR1, HCDR2, and HCDR3, and the VL1 and VL2 include LCDR1, LCDR2, and LCDR3. e. The VH1 domains are (for example, in order) i. HCDR1 having amino acid sequence sequence number 32, HCDR2 having amino acid sequence sequence number 33, and HCDR3 having amino acid sequence sequence number 34, or ii. HCDR1 having amino acid sequence sequence number 35, HCDR2 having amino acid sequence sequence number 36, and HCDR3 having amino acid sequence sequence number 37, or iii. HCDR1 having amino acid sequence number 38, HCDR2 having amino acid sequence number 39, and HCDR3 having amino acid sequence number 40. including, and f. The VL1 domains are (for example, in order) i. The LCDR1 having amino acid sequence sequence number 4, the LCDR2 having amino acid sequence sequence number 5, and the LCDR3 having amino acid sequence sequence number 6, or ii. The LCDR1 having amino acid sequence number 7, the LCDR2 having amino acid sequence number 8, and the LCDR3 having amino acid sequence number 9, or iii. LCDR1 having amino acid sequence number 10, LCDR2 having amino acid sequence number 11, and LCDR3 having amino acid sequence number 12. including, and g. The VH2 domains are (for example, in order) i. HCDR1 having amino acid sequence number 46, HCDR2 having amino acid sequence number 47, and HCDR3 having amino acid sequence number 48, or ii. HCDR1 having amino acid sequence number 49, HCDR2 having amino acid sequence number 50, and HCDR3 having amino acid sequence number 51, or iii. HCDR1 having amino acid sequence number 52, HCDR2 having amino acid sequence number 53, and HCDR3 having amino acid sequence number 54. including, and h. The VL2 domains are (for example, in order) i. The LCDR1 having amino acid sequence number 18, the LCDR2 having amino acid sequence number 19, and the LCDR3 having amino acid sequence number 20, or ii. The LCDR1 having amino acid sequence sequence number 21, the LCDR2 having amino acid sequence sequence number 22, and the LCDR3 having amino acid sequence sequence number 23, or iii. LCDR1 having amino acid sequence sequence number 24, LCDR2 having amino acid sequence sequence number 25, and LCDR3 having amino acid sequence sequence number 26. A multispecific antibody according to invention 1 or 2, comprising: [Invention 4] A multispecific antibody according to any one of inventions 1 to 3, comprising a lambda-type first light chain and a kappa-type second light chain. [Invention 5] The multispecific antibody according to Invention 4, wherein the first light chain is lambda type 1 and the second light chain is kappa type 4. [Invention 6] (a) The VL1 domain comprises amino acid sequence number 13, and (b) The VL2 domain comprises amino acid sequence number 27, and is a multispecific antibody according to any one of inventions 1 to 5. [Invention 7] a. The VH1 domain comprises amino acid sequence number 41, and b. The VL1 domain comprises amino acid sequence number 13, and c. The VH2 domain comprises amino acid sequence number 55, and d. The VL2 domain comprises amino acid sequence number 27, and is a multispecific antibody according to any one of inventions 1 to 6. [Invention 8] A multispecific antibody according to any one of Inventions 1 to 7, comprising a first light chain containing the amino acid sequence shown in SEQ ID NO: 14 and a second light chain containing the amino acid sequence shown in SEQ ID NO: 28. [Invention 9] A multispecific antibody according to any one of inventions 1 to 8, comprising a first heavy chain containing a heterodimerization modification and a second heavy chain containing a heterodimerization modification complementary to the heterodimerization modification of the first heavy chain. [Invention 10] The first and second heavy chains are human IgG1, and a) The heterodimerization modification of the first heavy chain comprises serine at position 366, alanine at position 368, and valine at position 407, and the heterodimerization modification of the second immu